Aminoglutethimide in advanced XXXX : clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.

@entity1 @entity701 @entity5 @entity0
We have conducted a multicenter randomized clinical trial comparing in advanced post-menopausal @entity0 @entity1 500 mg vs 1 g AG/day. The @entity701 dose was 40 mg/day in both groups. One hundred and seventy @entity1 have been randomized; 161 were evaluable for tolerability, 149 for effectiveness. Response rates were similar in both groups, 19 and 24% respectively for the 500 mg and 1 g groups. No difference was observed according to @entity5 site. Duration of response was the same in both groups (14 months), as was mean time to response (about 3 months). Survival (studies in 125 @entity1 ) was similar in both groups (responders and non-responders). No response could be obtained with 1 g after relapse or failure with 500 mg (n = 17). Tolerability was good in 91% of the 500 mg group @entity1 and 78% of the 1 g group @entity1 (P less than 0.03). It was poor in 4 and 15% respectively (P less than 0.03). Side-effects were the same in both groups but less frequent and less severe in the 500 mg group; however, these @entity1 more frequently had 'moon face'.
